How to make the best of NLRP3 inhibitors in patients with COVID-19?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00228-023-03518-z.pdf
Reference6 articles.
1. Vaz ES, Vassiliades SV, Giarolla J, Polli MC, Parise-Filho R (2023) Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies [published online ahead of print, 2023 Apr 20]. Eur J Clin Pharmacol 1–29
2. Zafar-Mohammadi K, Poursamimi J, Atabaki M (2022) NLRP3 inflammasome activation and its inhibitory drugs in connection with COVID-19 infection. Eur J Inflamm 20:1721727X221130984
3. Kow CS, Lee LH, Ramachandram DS, Hasan SS, Ming LC, Goh HP (2022) The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID-19: a meta-analysis of randomized trials. Immun Inflamm Dis 10(2):255–264
4. Dahms K, Mikolajewska A, Ansems K, Metzendorf MI, Benstoem C, Stegemann M (2023) Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis. Eur J Med Res 28(1):100
5. Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, Fragkou A, Rapti A, Damoulari C, Fantoni M, Kalomenidis I, Chrysos G, Angheben A, Kainis I, Alexiou Z, Castelli F, Serino FS, Tsilika M, Bakakos P, Nicastri E, Tzavara V, Kostis E, Dagna L, Koufargyris P, Dimakou K, Savvanis S, Tzatzagou G, Chini M, Cavalli G, Bassetti M, Katrini K, Kotsis V, Tsoukalas G, Selmi C, Bliziotis I, Samarkos M, Doumas M, Ktena S, Masgala A, Papanikolaou I, Kosmidou M, Myrodia DM, Argyraki A, Cardellino CS, Koliakou K, Katsigianni EI, Rapti V, Giannitsioti E, Cingolani A, Micha S, Akinosoglou K, Liatsis-Douvitsas O, Symbardi S, Gatselis N, Mouktaroudi M, Ippolito G, Florou E, Kotsaki A, Netea MG, Eugen-Olsen J, Kyprianou M, Panagopoulos P, Dalekos GN, Giamarellos-Bourboulis EJ (2021) Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med 27(10):1752–1760
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3